McKesson Takes 49% of Option Care as Home Infusion Market for Complex Biologics Grows

The Quick Take

• McKesson acquires 49% stake in Option Care Health as home infusion therapy demand grows for complex treatments
• Option Care stock surged on the news as the McKesson partnership validates the home-infusion market thesis
• Complex infusion treatments — biologics, IV medications — are increasingly shifting from hospitals to home sites
• McKesson's distribution infrastructure provides Option Care a nationwide logistics advantage for home delivery

McKesson's acquisition of a 49% stake in Option Care Health represents a strategic bet on the accelerating shift of complex drug infusions from hospital outpatient settings to the home and alternative-care sites. This transition is driven by both cost economics — home infusion is typically 40-60% cheaper than hospital-based infusion — and patient preference for home-based care. By taking a near-controlling stake rather than a full acquisition, McKesson preserves Option Care's independent operational identity while creating a strategic distribution partnership that leverages McKesson's pharmaceutical distribution scale across North America.

The market reaction — Option Care stock surging — validates investor enthusiasm for the home infusion sector thesis. The partnership creates a defensive moat for Option Care against rival home infusion operators like BioPlus and CVS Health's specialty pharmacy division, which lack an equivalent distribution partnership of McKesson's scale. For McKesson itself, the 49% stake is an extension of its strategy to move beyond pure drug distribution into higher-margin specialty services. The structuring as a minority stake rather than full acquisition also manages regulatory scrutiny risk in an environment where large pharma mergers face extended antitrust review.

Healthcare investors should track Option Care's revenue growth in its biologics infusion segment — this is the highest-margin, fastest-growing component of the home infusion market, driven by newer specialty drugs that require IV administration. The macro variable that determines the success of the McKesson-Option Care partnership is reimbursement policy: CMS coverage rates for home infusion directly affect the economic case for expanding beyond hospital settings. Any favorable policy changes on Medicare or Medicaid home infusion reimbursement would be a significant positive catalyst.

Synthesized from 1 source.